Affordable Access

Involvement of peripheral dopamine receptors in the antihypertensive effect of a new ergoline derivative (355/1057).

Authors
  • Salvati, P
  • Bianchi, G
Type
Published Article
Journal
Archives internationales de pharmacodynamie et de thérapie
Publication Date
Apr 01, 1985
Volume
274
Issue
2
Pages
291–304
Identifiers
PMID: 4026460
Source
Medline
License
Unknown

Abstract

Oral administration of a new ergoline derivative (355/1057) produced a sustained arterial hypotension in conscious SHR rats. This effect was inhibited by the centrally acting DA blockers haloperidol and pimozide and by domperidone, a DA antagonist that does not cross the blood brain barrier. On the other hand it was unaffected by alpha- and beta-adrenoceptor blockers or by indomethacin. Moreover, the hypertension induced by 355/1057 in pithed SHR rats was reversed to hypotension when its alpha-adrenoceptor stimulant activity was inhibited by yohimbine. In anesthetized dogs the hypotensive activity of 355/1057 was abolished by pimozide but not by propranolol. In anesthetized cats, pretreatment with haloperidol prevented both the hypotensive activity of 355/1057 and its inhibitory effect on sympathetic nerve activity. These overall data suggest that 355/1057 lowers blood pressure in different species mainly by stimulating peripheral dopamine receptors.

Report this publication

Statistics

Seen <100 times